Evidence map›Paper›PMID 39594638›Full record

ReviewCells2024

Understanding Myelodysplasia and Inflammation Through the Lense of VEXAS Syndrome: A Review.

Louis Wolff, Leo Caratsch, Lin-Pierre Zhao, Sabine Blum, Denis Comte

Abstract readReview
In one paragraph

Review in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Vexas Syndrome: A Multisystem Challenge with Sweet Syndrome and Myelodysplastic Syndrome.European journal of case reports in internal medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Louis WolffDepartment of Internal Medicine, Erasme Hospital, Brussels University Hospital, Université Libre de Bruxelles (ULB), Route de Lennik 808, 1070 Brussels, Belgium.
Leo CaratschDepartment of Medicine, Division of Internal Medicine, Lausanne University Hospital (CHUV), University of Lausanne, 1005 Lausanne, Switzerland.ORCID 0009-0000-0585-0731
Lin-Pierre ZhaoAssistance Publique des Hôpitaux de Paris (AP-HP), Department of Hematology, Hôpital Saint-Louis, Université de Paris, 75010 Paris, France.
Sabine BlumDivision of Hematology and Hematology Central Laboratory, Lausanne University Hospital (CHUV), University of Lausanne, 1005 Lausanne, Switzerland.
Denis ComteDepartment of Medicine, Division of Internal Medicine, Lausanne University Hospital (CHUV), University of Lausanne, 1005 Lausanne, Switzerland.ORCID 0000-0002-6605-1498

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

VEXAS syndrome, a monogenic X-linked disorder resulting from mutations in the UBA1 gene, has emerged as a key model for unraveling the links between systemic inflammatory or autoimmune diseases (SIAD) and myelodysplastic syndromes (MD). This syndrome is characterized by the presence of vacuoles, X-linked inheritance, autoinflammation, and somatic mutation patterns, highlighting a unique intersection between genetic and immunological dysregulation. Apart from VEXAS, 10% to 30% of individuals diagnosed with MDS exhibit SIAD phenotypes, a significant increase compared to the 5% incidence in the general population. In this comprehensive review, we aim to elucidate the molecular mechanisms driving the pro-inflammatory environment in MDS, focusing on the contribution of VEXAS syndrome to this complex interplay. We examine how UBA1 mutations disrupt cellular homeostasis, triggering inflammatory pathways. Furthermore, we explore the broader implications of these findings for the pathogenesis of MDS, proposing that the inflammatory dysregulation of VEXAS may shed light on mechanisms of disease progression and identify potential therapeutic targets in MDS. Through an integrated analysis of genetic, immunological, and clinical data, this review seeks to deepen our understanding of the complex relationship between systemic inflammation and hematological malignancies, paving the way for new diagnostic and therapeutic strategies.

Indexed as

InflammationMyelodysplastic SyndromesAnimalsHumansMutationUbiquitin-Activating EnzymesUBA1 protein, humanUbiquitin-Activating Enzymesauto-immuneauto-inflammatorydysplasiainflammationMDSmyelodysplastic syndromesUBA1VEXAS

Identifiers

PMID39594638
PMCPMC11593025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.